Overview: CD79A Immunohistochemistry TestIntroduction: The CD79A Immunohistochemistry Test detects CD79A protein to diagnose B-cell lymphomas, causing lymph node swelling or fatigue. Aligned with 2023 WHO guidelines, it uses immunohistochemistry for high specificity, supporting cancer screening. This test is critical for guiding diagnosis, treatment planning, and improving outcomes in histopathology for patients with suspected B-cell lymphomas.
Other Names: CD79A IHC Assay, B-Cell Lymphoma IHC Test.
FDA Status: Laboratory-developed test (LDT), meeting histopathology standards for diagnostic accuracy.
Historical Milestone: CD79A testing began in the 1990s with lymphoma research. Immunohistochemistry-based methods improved in the 2000s, enhancing diagnostic precision.
Purpose: Detects CD79A to diagnose B-cell lymphomas, guides treatment, and evaluates patients with lymph node swelling or fatigue.
Test Parameters: 1. CD79A Protein
Pretest Condition: No fasting required. Collect tissue via biopsy. Report history of lymph node swelling, fatigue, or lymphoma symptoms.
Specimen: 0.5-2 cma³ tissue (FFPE). Transport in a biohazard container.
Sample Stability at Room Temperature: 7 days
Sample Stability at Refrigeration: Not refrigerated
Sample Stability at Frozen: Not frozen
Medical History: Document lymph node swelling, fatigue, night sweats, or family history of lymphomas. Include current medications, especially rituximab.
Consent: Written consent required, detailing the tests purpose, lymphoma implications, and risks of biopsy.
Procedural Considerations: Uses immunohistochemistry to detect CD79A in lymphoid tissue. Results are available in 1-2 days, supporting rapid clinical decisions. Performed in laboratories, often for B-cell lymphoma diagnosis.
Factors Affecting Result Accuracy: Improper tissue fixation or processing can affect results. Low tissue quality may reduce staining accuracy.
Clinical Significance: Positive CD79A staining confirms B-cell lymphoma, guiding rituximab or chemotherapy. Negative staining may require further lymphoma marker testing.
Specialist Consultation: Consult a hematologist or oncologist for result interpretation and treatment planning.
Additional Supporting Tests: CD20 IHC, BCL-2 IHC, or flow cytometry to confirm B-cell lymphoma diagnosis.
Test Limitations: Not specific to one B-cell lymphoma; other conditions may express CD79A. Clinical correlation is needed.
References: WHO Lymphoma Guidelines, 2023; Blood, Swerdlow SH, 2022.
